Healthy males between 18 and 45 years of age (inclusive). 
Body mass index to be between 18 to 30 kg/m2 (inclusive) as calculated by weight(Kg)/height(m2). 
Subjects were to have no clinically significant abnormal findings on physical examination, ECG, medical history, or clinical laboratory results during screening. 
Subjects were to, in the opinion of the investigator, have no clinically significant abnormal findings of renal and hepatic function as determined by serum creatinine, total bilirubin, and transaminase levels. 
Subjects were to be non-users of tobacco products (minimum of 6 months prior to the start of the study). 
Subjects were to have a negative screen for HIV I and II, HBsAg, and antibody to Hepatitis C virus. 
Subjects were to have a negative urine screen for alcohol, drugs of abuse (screening only), and cotinine. 
Subjects were to use an appropriate barrier method of contraception (condom and spermicide) in addition to having their female partner use another form of barrier contraception (e.g.female condom or occlusive cap with spermicide) during the study and for 3 months following administration of the study drug. 
Subjects were able to comply with the protocol and the restrictions and assessments therein. 
Subjects were to give voluntary written informed consent to participate in the trial. 

NCT01322464_inc_T1
Condition
Healthy
NCT01322464_inc_T2
Value
between 18 and 45 years
NCT01322464_inc_T3
Person
age
NCT01322464_inc_T4
Measurement
Body mass index
NCT01322464_inc_T5
Value
between 18 to 30 kg/m2
NCT01322464_inc_T6
Qualifier
clinically significant
NCT01322464_inc_T8
Condition
abnormal findings
NCT01322464_inc_T9
Procedure
physical examination
NCT01322464_inc_T10
Procedure
ECG
NCT01322464_inc_T11
Observation
medical history
NCT01322464_inc_T12
Procedure
clinical laboratory
NCT01322464_inc_T13
Temporal
during screening
NCT01322464_inc_T14
Negation
no
NCT01322464_inc_T15
Scope
physical examination, ECG, medical history, or clinical laboratory
NCT01322464_inc_T17
Measurement
serum creatinine
NCT01322464_inc_T18
Measurement
total bilirubin
NCT01322464_inc_T19
Measurement
transaminase levels
NCT01322464_inc_T20
Measurement
hepatic function
NCT01322464_inc_T21
Measurement
renal function
NCT01322464_inc_T22
Qualifier
clinically significant
NCT01322464_inc_T23
Condition
abnormal findings
NCT01322464_inc_T24
Scope
renal and hepatic function
NCT01322464_inc_T25
Scope
serum creatinine, total bilirubin, and transaminase levels
NCT01322464_inc_T26
Negation
no
NCT01322464_inc_T27
Condition
users of tobacco products
NCT01322464_inc_T28
Negation
non
NCT01322464_inc_T29
Temporal
minimum of 6 months prior to the start of the study
NCT01322464_inc_T30
Reference_point
the start of the study
NCT01322464_inc_T31
Measurement
screen for HIV I
NCT01322464_inc_T32
Measurement
screen for HIV II
NCT01322464_inc_T33
Value
negative
NCT01322464_inc_T34
Measurement
HBsAg
NCT01322464_inc_T35
Measurement
antibody to Hepatitis C virus
NCT01322464_inc_T36
Measurement
urine screen for alcohol
NCT01322464_inc_T37
Measurement
urine screen for drugs of abuse
NCT01322464_inc_T38
Measurement
urine screen for cotinine
NCT01322464_inc_T39
Value
negative